Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: ("physician" OR "physical")
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
language:"English"
product_txtF_mv:"National Center for Biotechnology Information"
Search alternatives
:
"physician" »
"physicians"
Showing
1
-
17
of
17
Search:
'("physician" OR "physical")'
,
query time: 0.57s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
CADTH Canadian drug expert committee recommendation: Naltrexone hydrochloride and bupropion hydrochloride (Contrave -- Bausch Health, Canada Inc.) : indication: an adjunct to a red...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... as an adjunct to a reduced-calorie diet and increased
physical
activity for chronic weight management in adults...
”
Read Now
2
CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis
Published 2018
CADTH
“
...
physician
with experience in the diagnosis and management of GCA. A reduction in price...
”
Read Now
3
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemi...
Published 2018
CADTH
“
... is prescribed by a
physician
with experience in the diagnosis and management of hereditary tyrosinemia type-1...
”
Read Now
4
CADTH Canadian Drug Expert Committee recommendation: Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease
Published 2018
CADTH
“
...
physician
with experience in the diagnosis and management of PD. Reduction in price...
”
Read Now
5
CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis
Published 2018
CADTH
“
...
physician
with experience in the diagnosis and management of GCA. A reduction in price...
”
Read Now
6
CADTH Canadian drug expert committee recommendation: Lanadelumab (Takhzyro -- shire pharma Canada ULC) : indication: for the routine prevention of attacks of hereditary angioedema...
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
.... The diagnosis of HAE type I or II is made by a specialist
physician
who has experience in the diagnosis of HAE...
”
Read Now
7
CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... in patients with disease activity, based on the
physician
assessment...
”
Read Now
8
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemi...
Published 2018
CADTH
“
... is prescribed by a
physician
with experience in the diagnosis and management of hereditary tyrosinemia type-1...
”
Read Now
9
CADTH Canadian drug expert committee recommendation: Lanadelumab (Takhzyro -- shire pharma Canada ULC) : indication: for the routine prevention of attacks of hereditary angioedema...
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
.... The diagnosis of HAE type I or II is made by a specialist
physician
who has experience in the diagnosis of HAE...
”
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary ty...
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... in patients with an established diagnosis of HT-1. The drug is prescribed by a
physician
with experience...
”
Read Now
11
CADTH Canadian Drug Expert Committee recommendation: Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease
Published 2018
CADTH
“
...
physician
with experience in the diagnosis and management of PD. Reduction in price...
”
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis C virus infection
Published 2018
CADTH
“
...
physician
with experience in the diagnosis and management of HCV infection. Drug plan cost for SOF/VEL/VOX...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... in patients with disease activity, based on the
physician
assessment...
”
Read Now
14
CADTH Canadian drug expert committee recommendation: Cyclosporine 0.1% (Verkazia -- Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children f...
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
... scale. 3. Severity of signs and symptoms of VKC should be documented by the treating
physician
...
”
Read Now
15
CADTH Canadian Drug Expert Committee recommendation: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis C virus infection
Published 2018
CADTH
“
...
physician
with experience in the diagnosis and management of HCV infection. Drug plan cost for SOF/VEL/VOX...
”
Read Now
16
CADTH Canadian drug expert committee recommendation: Cyclosporine 0.1% (Verkazia -- Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children f...
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
... scale. 3. Severity of signs and symptoms of VKC should be documented by the treating
physician
...
”
Read Now
17
CADTH Canadian drug expert committee recommendation: Siponimod (Mayzent -- Novartis Pharmaceuticals Canada Inc.) : indication : secondary progressive multiple sclerosis
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... activity, to delay the progression of
physical
disability. Siponimod isa sphingosine 1-phosphate receptor...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Clear Filter
Language: English
Clear Filter
Collection: National Center for Biotechnology Information
Year of Publication
From:
To:
Classification
610 - Medicine & health
17
330 - Economics
9
140 - Specific philosophical schools
4
700 - The arts; fine & decorative arts
2
Language
English
Collection
National Center for Biotechnology Information
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
17
Recently Uploaded
Last Month
2
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&filter%5B%5D=language%3A%22English%22&filter%5B%5D=product_txtF_mv%3A%22National+Center+for+Biotechnology+Information%22&lookfor=%28%22physician%22+OR+%22physical%22%29&type=AllFields
Send by Email
×
Loading...